BBIO BridgeBio Pharma Inc

USD 27.12 0.00 0
Icon

BridgeBio Pharma Inc (BBIO) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 27.12

0.00 (0.00)%

USD 5.07B

1.63M

USD 50.15(+84.92%)

USD 42.00 (+54.87%)

Icon

BBIO

BridgeBio Pharma Inc (USD)
COMMON STOCK | NSD
USD 27.12
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 5.07B

USD 42.00 (+54.87%)

USD 27.12

BridgeBio Pharma Inc (BBIO) Stock Forecast

Show ratings and price targets of :
USD 50.15
(+84.92%)

Based on the BridgeBio Pharma Inc stock forecast from 11 analysts, the average analyst target price for BridgeBio Pharma Inc is USD 50.15 over the next 12 months. BridgeBio Pharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BridgeBio Pharma Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, BridgeBio Pharma Inc’s stock price was USD 27.12. BridgeBio Pharma Inc’s stock price has changed by +5.28% over the past week, -2.66% over the past month and +48.85% over the last year.

No recent analyst target price found for BridgeBio Pharma Inc
No recent average analyst rating found for BridgeBio Pharma Inc

Company Overview BridgeBio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small m...Read More

https://bridgebio.com

3160 Porter Drive, Palo Alto, CA, United States, 94304

550

December

USD

USA

Adjusted Closing Price for BridgeBio Pharma Inc (BBIO)

Loading...

Unadjusted Closing Price for BridgeBio Pharma Inc (BBIO)

Loading...

Share Trading Volume for BridgeBio Pharma Inc Shares

Loading...

Compare Performance of BridgeBio Pharma Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for BBIO

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To BridgeBio Pharma Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD127.00B 31.94 20.00

ETFs Containing BBIO

Symbol Name BBIO's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About BridgeBio Pharma Inc (BBIO) Stock

Based on ratings from 11 analysts BridgeBio Pharma Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 19 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on BBIO's stock to indicate if its a good dividend stock.

Based on targets from 11 analysts, the average taret price for BBIO is USD 50.15 over the next 12 months. The maximum analyst target price is USD 70 while the minimum anlayst target price is USD 37.

Unfortunately we do not have enough data on BBIO's stock to indicate if its overvalued.

The last closing price of BBIO's stock was USD 27.12.

The most recent market capitalization for BBIO is USD 5.07B.

Based on targets from 11 analysts, the average taret price for BBIO is projected at USD 50.15 over the next 12 months. This means that BBIO's stock price may go up by +84.92% over the next 12 months.

We can't find any ETFs which contains BridgeBio Pharma Inc's stock.

As per our most recent records BridgeBio Pharma Inc has 550 Employees.

BridgeBio Pharma Inc's registered address is 3160 Porter Drive, Palo Alto, CA, United States, 94304. You can get more information about it from BridgeBio Pharma Inc's website at https://bridgebio.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...